Avid Bioservices, Inc.(CDMO)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

CDMO Avid Bioservices, Inc.

退市 09-25 06:04:55 EDT

12.49

+0.00

0.00%

最高12.49	最低12.49	成交量0.00
今开12.49	昨收12.49	日振幅0.00%
总市值7.99亿	流通市值6.32亿	总股本6,396万
成交额3,832万	换手率0.00%	流通股本5,062万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"CDMO","market":"US","secType":"STK","nameCN":"Avid Bioservices, Inc.","latestPrice":12.49,"timestamp":1738702800000,"preClose":12.49,"halted":4,"volume":0,"delay":0,"changeRate":0,"floatShares":50623090,"shares":63963302,"eps":-2.394638,"marketStatus":"退市","change":0,"latestTime":"09-25 06:04:55 EDT","open":12.49,"high":12.49,"low":12.49,"amount":38318611.149448,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.394638,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1790343000000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":12.49,"volumeRatio":0},"requestUrl":"/m/hq/s/CDMO","defaultTab":"news","newsList":[{"id":"2669465745","title":"泰德医药：收购工业用地作为规模化多肽CDMO生产基地","url":"https://stock-news.laohu8.com/highlight/detail?id=2669465745","media":"财中社","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669465745?lang=zh_cn&edition=full","pubTime":"2026-09-24 17:07","pubTimestamp":1790240820,"startTime":"0","endTime":"0","summary":"9月24日，泰德医药（03880）发布公告，宣布公司已完成位于杭州市钱塘区的一处工业用地及房产的收购，作为其规模化多肽CDMO生产基地项目一期的建设用地。项目一期占地面积约30亩，现有厂房建筑面积约1.35万平方米，预计将建设年产能为3-5吨的多肽原料药生产线。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609243883757855.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609243883757855.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["03880","CDMO","BK1141","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668965944","title":"开源证券：原料药板块业绩增速企稳回升 创新药及CDMO转型公司进入兑现期","url":"https://stock-news.laohu8.com/highlight/detail?id=2668965944","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668965944?lang=zh_cn&edition=full","pubTime":"2026-09-18 17:28","pubTimestamp":1789723709,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，开源证券发布研报称，国内原料药行业逐渐企稳回升，部分公司积极布局创新药赛道，持续拓展公司天花板，有望进入收获期。开源证券主要观点如下：原料药板块：业绩增速企稳回升，创新药及CDMO转型公司进入兑现期随着原料药行业去库存逐步完成、落后产能加速出清，板块基本面开始出现改善迹象，营收及净利润已逐步触底回升，毛利率相对稳定，估值水平呈现修复趋势。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1498011.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4139","159992","BK1161","CDMO","IBBQ","BK1574","LNGR","06978","161027","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667798911","title":"PROBIO与昆拓宣布达成战略合作，为先进疗法提供CDMO-CRO一体化解决方案。","url":"https://stock-news.laohu8.com/highlight/detail?id=2667798911","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667798911?lang=zh_cn&edition=full","pubTime":"2026-09-16 22:07","pubTimestamp":1789567643,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["CDMO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667236686","title":"四川双马：CDMO业务成功切入欧美主流市场，已与美、欧多家知名生物科技公司建立合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2667236686","media":"财闻","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667236686?lang=zh_cn&edition=full","pubTime":"2026-09-15 21:31","pubTimestamp":1789479060,"startTime":"0","endTime":"0","summary":"9月15日，四川双马(000935.SZ)发布投资者关系活动记录表。其中指出，CDMO业务成功切入欧美主流市场，已与美国、欧洲多家知名生物科技公司建立合作。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-09-15/doc-inirxpis3668545.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0004","GDOC","BK0235","IEIH","BK4585","AGNG","BK4139","SYNB","HBImain","159837","BK0021","CDMO","BK0028","BK4581","LNGR","MEDX","XBI","BK4588","000935","IBBJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667691412","title":"智通港股早知道 | 国产创新药WCLC数据密集兑现 投行看好中国CRO/CDMO复苏明确","url":"https://stock-news.laohu8.com/highlight/detail?id=2667691412","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667691412?lang=zh_cn&edition=full","pubTime":"2026-09-15 07:29","pubTimestamp":1789428595,"startTime":"0","endTime":"0","summary":"WCLC临床数据密集兑现，国内外投行相继看好中国CRO/CDMO复苏明确9月12日至15日，2026年世界肺癌大会在韩国首尔举行，多项国产创新药临床数据集中亮相，中国新药入选口头报告19项、小型口头报告45项，双双刷新历史纪录，肺癌领域ADC与双抗数据成为焦点。经初步测算，本次交易完成后，一汽股份将成为公司第二大和具有战略影响力的股东;本次交易预计构成重大资产重组及关联交易，不构成公司实际控制人变更，不构成重组上市。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495955.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1144","LU1226288170.HKD","LU1152091754.HKD","02889","CDMO","IE00BZ08YT58.USD","KCAI","LU1008478684.HKD","LU1328277881.USD","159992","IE0008369823.USD","LU0314109678.HKD","LU1226287875.USD","BK1191","IE00B543WZ88.USD","BK1119","06871","KURE","LU1951186391.HKD","BK1183","LU0140636845.USD","LU0326950275.SGD","SG9999004220.SGD","VXUS","LU0501845795.SGD","BK4588","06978","BK4585","LU1813983027.USD","LU1993786604.SGD","LU1960683339.HKD","01093","IE0008368742.USD","BK1521","01911","IE00B5MMRT66.SGD","LU2039709279.SGD","LU1226287529.USD","HK0000165453.HKD","02238","LU0315179316.USD","IBBQ","BK1161","BK4139","LU1226287792.SGD","BK1539","LNGR","BK1574","BK1147","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666267514","title":"中信证券：上半年投融资活跃推动CRO量价齐升，新分子需求催化CDMO订单兑现","url":"https://stock-news.laohu8.com/highlight/detail?id=2666267514","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666267514?lang=zh_cn&edition=full","pubTime":"2026-09-11 08:42","pubTimestamp":1789087362,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK1564","BK0276","LU2495084118.USD","LU2148510915.USD","06030","BK0196","LU2580892862.HKD","LU0405327494.USD","LU1064130708.USD","LU1781817850.SGD","CDMO","LU2289578879.USD","LU1794554557.SGD","LU1820825898.SGD","BK1516","LU1328615791.USD","LU1064131003.USD","BK0183","BK4139","LU1655091616.SGD","LU2580892789.USD","LU1255011170.USD","LU1997245177.USD","BK0012","BK1147","LU1146622755.USD","BK0188","LU0405327148.USD","LU1580142542.USD","BK0028","BK1521","LU1997244956.HKD","LU1997245094.SGD","LU1720050803.USD","600030"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664587386","title":"药石科技：拟投建南京CDMO创新基地 总投资约20亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2664587386","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664587386?lang=zh_cn&edition=full","pubTime":"2026-09-03 17:37","pubTimestamp":1788428254,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["CDMO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662713592","title":"上海：到2030年，战略性新兴产业增加值达2.1万亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2662713592","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662713592?lang=zh_cn&edition=full","pubTime":"2026-08-26 19:05","pubTimestamp":1787742300,"startTime":"0","endTime":"0","summary":"据上海市人民政府官网2026年8月26日消息，《上海市战略性新兴产业发展“十五五”规划》近日发布。到2030年，战略性新兴产业增加值达2.1万亿元，工业战略性新兴产业总产值占规模以上工业总产值比重达50%以上，三大先导产业制造业年均增速达10%以上。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/jjxw/2026-08-26/doc-iniprytn5569476.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-08-26/doc-iniprytn5569476.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["CDMO","5RE.SI","AGIX","MEDX","VTHR","QTOC","CHAT","LNGR","BK6511","ARTY","BK4139","BK6092","AIPO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661567229","title":"美银证券：CDMO业务上行周期带动康龙化成(03759)增长 目标价升至38.4港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2661567229","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661567229?lang=zh_cn&edition=full","pubTime":"2026-08-24 15:27","pubTimestamp":1787556446,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，美银证券发布研报称，将康龙化成(03759)目标价由32.3港元上调至38.4港元，维持\"买入\"评级。康龙化成2026年上半年收入年度同比增长17.9%至76亿元人民币，各业务均录得增长，其中实验室服务收入年度同比增长13.7%，CDMO收入年度同比增长32.8%，临床开发收入年度同比增长13.8%，CDMO毛利率提升2.7个百分点，但被实验室及临床服务受压所部分抵消。考虑到CDMO、实验室服务及临床开发业务快速增长，以及全球口服GLP-1业务的能见度，美银证券将康龙化成2026至2028年收入预测分别上调4%、8%及12%，看好该公司CDMO业务上行周期可带来增长。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1484124.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03759","EWH","300759","161027","CDMO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661606422","title":"东曜药业-B(01875)发布中期业绩 总收入2.46亿元 CDMO业务高速增长 自研产品加速出海","url":"https://stock-news.laohu8.com/highlight/detail?id=2661606422","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661606422?lang=zh_cn&edition=full","pubTime":"2026-08-21 19:55","pubTimestamp":1787313304,"startTime":"0","endTime":"0","summary":"智通财经APP讯，东曜药业-B 发布截至2026年6月30日止六个月中期业绩，2026年上半年，公司合约开发和制造组织项目管线及在手订单快速增长。CMC项目总数由2025年6月30日的98个增至2026年6月30日的134个。2026年上半年，公司总收入为人民币2.46亿元。该下降主要由于自研产品销售收入减少所致，而CDMO业务毛利随该板块业务增长相应提升。2026年上半年，公司持续高效履约，稳步保障全球客户订单交付，CDMO业务实现大幅增长。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1483573.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4139","CDMO","BK1574","BK1161","01875"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658598104","title":"医药投资向制造端扩散，原料药、CDMO等现配置窗口","url":"https://stock-news.laohu8.com/highlight/detail?id=2658598104","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658598104?lang=zh_cn&edition=full","pubTime":"2026-08-10 17:06","pubTimestamp":1786352768,"startTime":"0","endTime":"0","summary":"以多肽、ADC、小核酸等为代表的新型分子药物正处于高速迭代期，这为医药制造业提供了持续的结构性增量来源，使其区别于需求饱和后总量萎缩的传统制造业。　　近日，全球医药研发生产外包龙头药企披露其2026年半年度业绩，上半年实现归母扣非净利润105.72亿元，同比增长89.39%。展望未来，医药制造与创新药有望形成双引擎，共同引领医药板块逐步走向复苏。　　医药制造的涵盖范围很广，CDMO、原料药和医疗器械是我们比较看好的三个方向。","market":"hk","thumbnail":" http://caiji.3g.cnfol.com/colect/202608/10/20260810555644.jpeg","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202608/10/20260810555644.jpeg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/shichangjuejin/20260810/32330541.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1574","BK1161","BK1515","BK4139","159938","09939","CDMO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657753693","title":"港股异动 | 创胜集团医药-B(06628)午前涨超11% 拟1.9亿元出售CDMO资产","url":"https://stock-news.laohu8.com/highlight/detail?id=2657753693","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657753693?lang=zh_cn&edition=full","pubTime":"2026-08-07 11:27","pubTimestamp":1786073234,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，创胜集团医药-B午前涨超11%，截至发稿，涨11.22%，报1.14港元，成交额34.07万港元。消息面上，创胜集团医药-B发布公告，于2026年8月6日，卖方与买方杭州明德生物医药技术有限公司订立资产购买协议，卖方有条件同意出售，而买方有条件同意购买 CDMO资产，总代价为人民币1.9亿元。于二期完成后，本公司将不再于CDMO资产中拥有任何权益。CDMO资产主要包括本集团过往提供CDMO服务所涉及的GMP生产设施。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1477169.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","CDMO","VXUS","BK1515","BK1574","BK4585","BK4139","159938","09939","KCAI","BK4588","06628"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657766762","title":"创胜集团医药-B出售CDMO资产 交易总价1.9亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2657766762","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657766762?lang=zh_cn&edition=full","pubTime":"2026-08-07 08:50","pubTimestamp":1786063800,"startTime":"0","endTime":"0","summary":"8月7日，创胜集团医药-B（06628）发布公告，董事会于2026年8月6日宣布，公司全资附属公司杭州奕安济世生物药业有限公司与买方杭州明德生物医药技术有限公司签订了资产购买协议，出售CDMO资产，交易总价为1.9亿元。交易完成后，公司将不再持有CDMO资产的任何权益。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608073834582979.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608073834582979.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["CDMO","BK1574","BK1515","BK1161","BK4139","06628","159938","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657669070","title":"创胜集团医药-B(06628.HK)拟1.9亿元出售CDMO资产","url":"https://stock-news.laohu8.com/highlight/detail?id=2657669070","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657669070?lang=zh_cn&edition=full","pubTime":"2026-08-07 06:36","pubTimestamp":1786055801,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["CDMO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655832649","title":"【券商聚焦】国泰海通证券：全球多肽CDMO进入产能扩张周期","url":"https://stock-news.laohu8.com/highlight/detail?id=2655832649","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655832649?lang=zh_cn&edition=full","pubTime":"2026-07-29 09:21","pubTimestamp":1785288070,"startTime":"0","endTime":"0","summary":"国内外的多肽CDMO公司均加大对于产能的投资建设，尤其注重从临床前到商业化生产的一站式服务能力建设。2026年4月，凯莱英医药与天津经开区管委会签署合作备忘录，在天津经开区持续扩建化学大分子创新药CDMO研发生产基地，预计投资规模达20亿元人民币。","market":"us","thumbnail":"https://static.szfiu.com/news/20250109/MWIyNWQwZjQ4NTQyNjI4OTI5NDE=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MWIyNWQwZjQ4NTQyNjI4OTI5NDE=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1986985","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1610","601211","KCE","01801","SG9999002463.SGD","LU0181495838.USD","BK1141","LU0417516738.SGD","161027","02611","02616","BK1574","BK1588","KURE","LU0359202008.SGD","LU1328277881.USD","LU0307460666.USD","01877","01177","IE00B0JY6N72.USD","LU0979878070.USD","BK1564","CDMO","LU0052750758.USD","06160","IE00B543WZ88.USD","LU1719994722.HKD","LU1251922891.USD","BK1147","LU0051755006.USD","06185","LU2476274308.USD","09995","09926","LU1720050803.USD","01093","02142","HK0000165453.HKD","02269","LU0348784397.USD","LU0561508036.HKD","LU0588546209.SGD","BK1583","LU0634319403.HKD","LU1008478684.HKD","LU0067412154.USD","LU2242644610.SGD","IE00B5MMRT66.SGD","09688"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653772632","title":"中信建投：2026年国内CRO/CDMO行业的新签订单及业绩会加速增长，带动CXO产业链进入新一轮发展阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2653772632","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653772632?lang=zh_cn&edition=full","pubTime":"2026-07-24 08:20","pubTimestamp":1784852419,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4139","CXO","CDMO","WX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646333550","title":"港股异动 | 创胜集团医药-B(06628)涨近4% 近期收到HiCB对外授权里程碑付款 CDMO业务取得稳步进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2646333550","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2646333550?lang=zh_cn&edition=full","pubTime":"2026-06-26 11:04","pubTimestamp":1782443087,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，创胜集团医药-B涨近4%，截至发稿，涨3.77%，报1.1港元，成交额13.63万港元。消息面上，近期，创胜集团医药-B发布公告，公司已收到来自其HiCB平台对外授权的一笔里程碑付款人民币700万元。迄今为止，创胜集团已成功完成关键可交付条件。同时，创胜集团的CDMO业务亦取得稳步进展。创胜集团目前亦就其他高潜力项目洽谈合约，包括综合IND开发项目、siRNA GMP药品生产、可开发性评估及为全球客户进行材料生产。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1459218.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1574","09939","BK4585","BK4588","CDMO","159938","06628","BK4139","VXUS","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640520699","title":"新股消息 | 智享生物递表港交所 为中国第二大生物制剂CDMO公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2640520699","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2640520699?lang=zh_cn&edition=full","pubTime":"2026-06-01 21:36","pubTimestamp":1780320982,"startTime":"0","endTime":"0","summary":"在中国，生物制剂CDMO市场规模由2020年的人民币91亿元扩大至2025年的人民币325亿元，期间年复合增长率为28.9%。中国生物制剂CDMO行业竞争激烈且高度集中。全球至少有150家生物制剂CDMO公司，其中至少25家位于中国。2025年，中国生物制剂CDMO市场总规模达人民币325亿元。2025年，在专注抗体药物的本土生物制剂CDMO中，公司在中国生物制剂CDMO市场中以收入计位列第三。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1448756.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IPOS","BK4139","CDMO","HEXmain"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638689303","title":"公告精选︱康龙化成：拟20亿元新建新药商业化生产和CDMO研发生产服务基地；华塑控股：未从事PCB生产业务","url":"https://stock-news.laohu8.com/highlight/detail?id=2638689303","media":"格隆汇","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2638689303?lang=zh_cn&edition=full","pubTime":"2026-05-27 22:33","pubTimestamp":1779892385,"startTime":"0","endTime":"0","summary":"龙芯中科：拟定增募资不超23亿元","market":"us","thumbnail":"https://img7.gelonghui.com/column/2/111.png?guru_height=540&guru_width=375","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/2/111.png?guru_height=540&guru_width=375"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/4950239","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["BK0216","CDMO","BK0236","BK0102","PCB","BK1141","BK1576","BK4211","300759","03759","BK4139","000509","BK0095","BK0145"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638659263","title":"创胜集团医药-B(06628)公布收到HiCB对外授权里程碑付款及CDMO业务稳步增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2638659263","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2638659263?lang=zh_cn&edition=full","pubTime":"2026-05-26 16:35","pubTimestamp":1779784520,"startTime":"0","endTime":"0","summary":"智通财经APP讯，创胜集团医药-B 发布公告，公司已收到来自其HiCB平台对外授权的一笔里程碑付款人民币700万元，同时其CDMO业务亦取得重大进展。迄今为止，创胜集团已成功完成关键可交付条件。同时，创胜集团的CDMO业务亦取得稳步进展。随着HiCB对外授权项目取得进展以及CDMO业务持续扩张，创胜集团依然处于有利位置，以推动可持续增长并为其合作伙伴及股东创造长期价值。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1445970.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4139","159938","BK1515","06628","09939","BK1161","BK1574","CDMO"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.avidbio.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":0.006},{"period":"1month","weight":0.0017},{"period":"3month","weight":0.0524},{"period":"6month","weight":0.2099},{"period":"1year","weight":0.1605},{"period":"ytd","weight":0.125}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Avid Bioservices, Inc.最初于1981年6月在美国加州注册成立，并于1996年9月25日在美国特拉华州重新合并。该公司是一家专门的合同开发和制造组织（“CDMO”），提供从工艺开发到当前良好制造实践的全方位服务（“CGMP”）临床和商业制造，专注于从哺乳动物细胞培养中提取生物制药物。","yearOnYearQuotes":[{"month":1,"riseRate":0.645161,"avgChangeRate":0.245054},{"month":2,"riseRate":0.580645,"avgChangeRate":0.056406},{"month":3,"riseRate":0.466667,"avgChangeRate":-0.035156},{"month":4,"riseRate":0.4,"avgChangeRate":-0.032334},{"month":5,"riseRate":0.516129,"avgChangeRate":0.109027},{"month":6,"riseRate":0.419355,"avgChangeRate":0.007765},{"month":7,"riseRate":0.322581,"avgChangeRate":0.039463},{"month":8,"riseRate":0.354839,"avgChangeRate":0.002481},{"month":9,"riseRate":0.387097,"avgChangeRate":-0.046446},{"month":10,"riseRate":0.354839,"avgChangeRate":-0.040707},{"month":11,"riseRate":0.548387,"avgChangeRate":0.073378},{"month":12,"riseRate":0.419355,"avgChangeRate":0.023819}],"exchange":"NASDAQ","name":"Avid Bioservices, Inc.","nameEN":"Avid Bioservices, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Avid Bioservices, Inc.(CDMO)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Avid Bioservices, Inc.(CDMO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Avid Bioservices, Inc.,CDMO,Avid Bioservices, Inc.股票,Avid Bioservices, Inc.股票老虎,Avid Bioservices, Inc.股票老虎国际,Avid Bioservices, Inc.行情,Avid Bioservices, Inc.股票行情,Avid Bioservices, Inc.股价,Avid Bioservices, Inc.股市,Avid Bioservices, Inc.股票价格,Avid Bioservices, Inc.股票交易,Avid Bioservices, Inc.股票购买,Avid Bioservices, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Avid Bioservices, Inc.(CDMO)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Avid Bioservices, Inc.(CDMO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}